在接受Keytruda治疗2年的患者中,3-5级的TRAE发生率为15.4%。 原文出处:First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ...
“Before 2014, the five-year survival rate for patients in the U.S. with advanced non-small cell lung cancer was only 5%,”Martin Reck, MD, PhD, of theGerman Center of Lung ResearchandLung Clinic Grosshansdorf, in Germany, said in apress release. “KEYN...
在接受Keytruda治疗2年的患者中,3-5级的TRAE发生率为15.4%。 原文出处:First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ...
参考资料: [1] Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer, Retrieved June 1, 2019, from https://www./about-asco/press-center/news-releases/pembrolizumab-increases-historic-survival-rate-certain-people [2] Front-Line Pembrolizumab Is Pro...
[4] KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC). Retrieved October 20, 2023 from https://www.merc...
Cho:I think it means that we can expect a better prognosis. Lung cancer has long been the No. 1 killer cancer. As a surgeon, it's always a burden to think that the patient's prognosis is not good. However, when you know that you can expect a better prognosis and survival rate thro...
The five-year survival rate for patients diagnosed with gastric cancer at an advanced stage is only 6%. About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) ther...
Advanced non-small cell lung cancer (advanced NSCLC) When used as an initial therapy, Keytruda + chemotherapy has been shown to help patients with advanced nonsquamousNSCLClive longer than using chemotherapy alone. In one study, half of the patients receiving Keytruda + chemotherapy were alive with...
of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. KEYTRUDA, as a single agent, is also indicate...
“The majority of patients withgastric cancerare diagnosed at an advanced stage, at which point they face a poor prognosis with a five-year survival rate of 6%,” said Dr. Zev A. Wainberg, professor of medicine at University of California, Los Angeles School of Medicine and co...